Short Interest of The Day: Does Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Have Gas After Even More Sellers Involved?

November 23, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest of The Day: Does Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Have Gas After Even More Sellers Involved?

The stock of Aimmune Therapeutics Incorporated (NASDAQ:AIMT) registered an increase of 3.16% in short interest. AIMT’s total short interest was 3.00 million shares in November as published by FINRA. Its up 3.16% from 2.91 million shares, reported previously. With 105,800 shares average volume, it will take short sellers 28 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Incorporated’s float is 12.82%. About 318,645 shares traded hands or 25.62% up from the average. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 76.50% since April 21, 2016 and is uptrending. It has outperformed by 71.17% the S&P500.

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company has a market cap of $1.05 billion. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy , is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It currently has negative earnings. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101.

Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage

Out of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aimmune Therapeutics has been the topic of 5 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, November 17. The stock has “Overweight” rating given by Piper Jaffray on Monday, August 31. The rating was initiated by Bank of America with “Buy” on Monday, August 31. The firm has “Outperform” rating given on Monday, August 31 by Credit Suisse. The stock has “Mkt Outperform” rating given by JMP Securities on Monday, September 26.

AIMT Company Profile

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, incorporated on June 24, 2011, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

More notable recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 12, 2015, also Quotes.Wsj.com with their article: “News Aimmune Therapeutics Inc.AIMT” published on July 31, 2015, Businesswire.com published: “Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health …” on November 04, 2016. More interesting news about Aimmune Therapeutics Inc (NASDAQ:AIMT) were released by: Businesswire.com and their article: “Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and …” published on November 14, 2016 as well as Businesswire.com‘s news article titled: “Aimmune Therapeutics Completes and Exceeds North American Enrollment Target …” with publication date: September 20, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>